GT Medical Technologies: Pioneering a New Paradigm for Brain Tumor Radiotherapy
GT Medical Technologies’ implant delivers radiation therapy directly to the bed of an excised brain tumor—a potential game-changer for people with highly proliferative, hard-to-treat tumors such as glioblastomas. Its GammaTile Therapy is now in use at 75 US hospitals and the firm has raised $26 million over the past three years—not bad for a company that launched its flagship product at the height of the pandemic.
Bridging Surgical Treatment and Chemoradiation for Glioblastoma Patients
GT Medical announced the first participant enrolled in the GammaTile Enhanced Stupp ALTernative (GESTALT) trial. While this trial is still in its infancy, if the results are favorable, it may influence protocols for treating glioblastomas (GBMs) and bridge the gap between surgery and chemoradiation.